Literature DB >> 22920906

The therapeutic target Hsp90 and cancer hallmarks.

Yoshihiko Miyata1, Hitoshi Nakamoto, Len Neckers.   

Abstract

Hsp90 is a major molecular chaperone that is expressed abundantly and plays a pivotal role in assisting correct folding and functionality of its client proteins in cells. The Hsp90 client proteins include a wide variety of signal transducing molecules such as protein kinases and steroid hormone receptors. Cancer is a complex disease, but most types of human cancer share common hallmarks, including self-sufficiency in growth signals, insensitivity to growth-inhibitory mechanism, evasion of programmed cell death, limitless replicative potential, sustained angiogenesis, and tissue invasion and metastasis. A surprisingly large number of Hsp90-client proteins play crucial roles in establishing cancer cell hallmarks. We start the review by describing the structure and function of Hsp90 since conformational changes during the ATPase cycle of Hsp90 are closely related to its function. Many co-chaperones, including Hop, p23, Cdc37, Aha1, and PP5, work together with Hsp90 by modulating the chaperone machinery. Post-translational modifications of Hsp90 and its cochaperones are vital for their function. Many tumor-related Hsp90-client proteins, including signaling kinases, steroid hormone receptors, p53, and telomerase, are described. Hsp90 and its co-chaperones are required for the function of these tumor-promoting client proteins; therefore, inhibition of Hsp90 by specific inhibitors such as geldanamycin and its derivatives attenuates the tumor progression. Hsp90 inhibitors can be potential and effective cancer chemotherapeutic drugs with a unique profile and have been examined in clinical trials. We describe possible mechanisms why Hsp90 inhibitors show selectivity to cancer cells even though Hsp90 is essential also for normal cells. Finally, we discuss the "Hsp90-addiction" of cancer cells, and suggest a role for Hsp90 in tumor evolution.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22920906      PMCID: PMC7553218          DOI: 10.2174/138161213804143725

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  271 in total

1.  The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome.

Authors:  W G An; T W Schulte; L M Neckers
Journal:  Cell Growth Differ       Date:  2000-07

Review 2.  Targeting the oncogene and kinome chaperone CDC37.

Authors:  Phillip J Gray; Thomas Prince; Jinrong Cheng; Mary Ann Stevenson; Stuart K Calderwood
Journal:  Nat Rev Cancer       Date:  2008-05-30       Impact factor: 60.716

3.  Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.

Authors:  Purva Bali; Michael Pranpat; James Bradner; Maria Balasis; Warren Fiskus; Fei Guo; Kathy Rocha; Sandhya Kumaraswamy; Sandhya Boyapalle; Peter Atadja; Edward Seto; Kapil Bhalla
Journal:  J Biol Chem       Date:  2005-06-02       Impact factor: 5.157

4.  Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228.

Authors:  Xiaodan Yu; Z Sheng Guo; Monica G Marcu; Len Neckers; Dao M Nguyen; G Aaron Chen; David S Schrump
Journal:  J Natl Cancer Inst       Date:  2002-04-03       Impact factor: 13.506

5.  Functional importance of heat shock protein 90 associated with insulin receptor on insulin-stimulated mitogenesis.

Authors:  Y Takata; T Imamura; M Iwata; I Usui; T Haruta; N Nandachi; M Ishiki; T Sasaoka; M Kobayashi
Journal:  Biochem Biophys Res Commun       Date:  1997-08-18       Impact factor: 3.575

6.  Expression of Hsp90 chaperone [corrected] proteins in human tumor tissue.

Authors:  Christina L McDowell; R Bryan Sutton; Wolfgang M J Obermann
Journal:  Int J Biol Macromol       Date:  2009-07-01       Impact factor: 6.953

Review 7.  Death-associated protein kinase (DAPK) and signal transduction: additional roles beyond cell death.

Authors:  Yao Lin; Ted R Hupp; Craig Stevens
Journal:  FEBS J       Date:  2009-10-26       Impact factor: 5.542

8.  Two human 90-kDa heat shock proteins are phosphorylated in vivo at conserved serines that are phosphorylated in vitro by casein kinase II.

Authors:  S P Lees-Miller; C W Anderson
Journal:  J Biol Chem       Date:  1989-02-15       Impact factor: 5.157

Review 9.  Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond.

Authors:  Georgios V Georgakis; Anas Younes
Journal:  Future Oncol       Date:  2005-04       Impact factor: 3.404

10.  The hsp90 molecular chaperone modulates multiple telomerase activities.

Authors:  Oyetunji A Toogun; Diane C Dezwaan; Brian C Freeman
Journal:  Mol Cell Biol       Date:  2007-10-22       Impact factor: 4.272

View more
  116 in total

1.  Inhibition of heat shock protein 90 alleviates steatosis and macrophage activation in murine alcoholic liver injury.

Authors:  Aditya Ambade; Donna Catalano; Arlene Lim; Andre Kopoyan; Scott A Shaffer; Pranoti Mandrekar
Journal:  J Hepatol       Date:  2014-05-22       Impact factor: 25.083

Review 2.  Hsp90 in Cancer: Transcriptional Roles in the Nucleus.

Authors:  Stuart K Calderwood; Len Neckers
Journal:  Adv Cancer Res       Date:  2015-10-12       Impact factor: 6.242

Review 3.  Chaperome heterogeneity and its implications for cancer study and treatment.

Authors:  Tai Wang; Anna Rodina; Mark P Dunphy; Adriana Corben; Shanu Modi; Monica L Guzman; Daniel T Gewirth; Gabriela Chiosis
Journal:  J Biol Chem       Date:  2018-11-08       Impact factor: 5.157

4.  Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response.

Authors:  Sanil Bhatia; Daniela Diedrich; Benedikt Frieg; Heinz Ahlert; Stefan Stein; Bertan Bopp; Franziska Lang; Tao Zang; Tobias Kröger; Thomas Ernst; Gesine Kögler; Andreas Krieg; Steffen Lüdeke; Hana Kunkel; Ana J Rodrigues Moita; Matthias U Kassack; Viktoria Marquardt; Friederike V Opitz; Marina Oldenburg; Marc Remke; Florian Babor; Manuel Grez; Andreas Hochhaus; Arndt Borkhardt; Georg Groth; Luitgard Nagel-Steger; Joachim Jose; Thomas Kurz; Holger Gohlke; Finn K Hansen; Julia Hauer
Journal:  Blood       Date:  2018-05-03       Impact factor: 22.113

5.  Synthesis and evaluation of a ring-constrained Hsp90 C-terminal inhibitor that exhibits neuroprotective activity.

Authors:  Zheng Zhang; Zhenyuan You; Rick T Dobrowsky; Brian S J Blagg
Journal:  Bioorg Med Chem Lett       Date:  2018-03-26       Impact factor: 2.823

Review 6.  Decanalizing thinking on genetic canalization.

Authors:  Kerry Geiler-Samerotte; Federica M O Sartori; Mark L Siegal
Journal:  Semin Cell Dev Biol       Date:  2018-05-24       Impact factor: 7.727

7.  Exploiting polarity and chirality to probe the Hsp90 C-terminus.

Authors:  Leah K Forsberg; Rachel E Davis; Virangika K Wimalasena; Brian S J Blagg
Journal:  Bioorg Med Chem       Date:  2018-04-13       Impact factor: 3.641

Review 8.  Beyond Alkylating Agents for Gliomas: Quo Vadimus?

Authors:  Vinay K Puduvalli; Rekha Chaudhary; Samuel G McClugage; James Markert
Journal:  Am Soc Clin Oncol Educ Book       Date:  2017

Review 9.  Tumour suppressor HLJ1: A potential diagnostic, preventive and therapeutic target in non-small cell lung cancer.

Authors:  Meng-Feng Tsai; Chi-Chung Wang; Jeremy Jw Chen
Journal:  World J Clin Oncol       Date:  2014-12-10

10.  Biasing Potential Replica Exchange Multisite λ-Dynamics for Efficient Free Energy Calculations.

Authors:  Kira A Armacost; Garrett B Goh; Charles L Brooks
Journal:  J Chem Theory Comput       Date:  2015-03-10       Impact factor: 6.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.